

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2021/260193 A1**

(43) International Publication Date  
30 December 2021 (30.12.2021)

(51) International Patent Classification:

A61P 25/28 (2006.01) A61K 39/00 (2006.01)  
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/EP2021/067536

(22) International Filing Date:

25 June 2021 (25.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/043,872 25 June 2020 (25.06.2020) US

(71) Applicants: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **TAN, Keith**; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6GH (GB). **SHERING, Craig**; 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **SIMS, John R.**; c/o Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **DAGE, Jeffrey L.**; c/o Eli Lilly and Company, Lilly Corporation Center, Indianapolis, Indiana 46285 (US).

(74) Agent: **MATHYS & SQUIRE LLP** et al.; The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42

(57) Abstract: The present invention relates to the prevention of neuronal axonal damage. More particularly, the present invention relates to the prevention neuronal axonal damage using binding members that selectively bind human amyloid beta 1-42 peptide (A $\beta$ 1-42), wherein the treatment of a patient with said binding member decreases the level of neurofilament light chain (NFL) in patients.

WO 2021/260193 A1